Mass. startup gets $30M boost to advance gene regulators

04/12/2013 | American City Business Journals · Xconomy

A Series A funding round led by Arch Venture Partners and Flagship Ventures has brought in $30 million to Syros Pharmaceuticals, which is developing treatment techniques based on advanced genetic sequencing and insights into how proteins control genetic expression in stem cells. The Watertown, Mass.-based biotech startup will use the money to expedite the discovery and development of proteins it calls super enhancers.

View Full Article in:

American City Business Journals · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care